Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -754,626 | -642,178 | -459,851 | -391,279 | -206,891 |
| Depreciation Amortization | 30,459 | 30,107 | 32,196 | 27,459 | 25,868 |
| Income taxes - deferred | N/A | -2,225 | 0 | N/A | N/A |
| Accounts receivable | -2,923 | 13,900 | 7,831 | 31,603 | -42,328 |
| Accounts payable and accrued liabilities | -1,182 | -15,057 | 19,010 | 17,382 | 9,158 |
| Other Working Capital | -63,777 | 61,424 | 138,783 | 47,300 | 123,054 |
| Other Operating Activity | 156,607 | 126,443 | 35,549 | 15,059 | 68,664 |
| Operating Cash Flow | $-635,442 | $-427,586 | $-226,482 | $-252,476 | $-22,475 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -38,054 | -23,496 | -32,180 | -32,415 | -32,417 |
| Net Acquisitions | N/A | -87,422 | N/A | N/A | N/A |
| Purchase Of Investment | -1,234,719 | -1,186,022 | -756,118 | -318,039 | -507,912 |
| Sale Of Investment | 1,284,806 | 788,263 | 427,648 | 755,620 | 320,634 |
| Other Investing Activity | -4,732 | -55 | 0 | 0 | 11,224 |
| Investing Cash Flow | $7,301 | $-508,732 | $-360,650 | $405,166 | $-208,471 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 149,902 | 278,607 | N/A | N/A |
| Debt Repayment | N/A | 0 | -19,997 | -42,102 | N/A |
| Common Stock Issued | 33,434 | 849,235 | 362,128 | 31,965 | 366,035 |
| Other Financing Activity | 391,623 | -131 | 0 | -53 | -170 |
| Financing Cash Flow | $425,057 | $999,006 | $620,738 | $-10,190 | $365,865 |
| Exchange Rate Effect | -377 | -5,145 | -154 | -8 | 207 |
| Beginning Cash Position | 446,658 | 389,115 | 355,663 | 213,171 | 78,045 |
| End Cash Position | 243,197 | 446,658 | 389,115 | 355,663 | 213,171 |
| Net Cash Flow | $-203,461 | $57,543 | $33,452 | $142,492 | $135,126 |
| Free Cash Flow | |||||
| Operating Cash Flow | -635,442 | -427,586 | -226,482 | -252,476 | -22,475 |
| Capital Expenditure | -38,054 | -23,496 | -32,180 | -32,415 | -32,417 |
| Free Cash Flow | -673,496 | -451,082 | -258,662 | -284,891 | -54,892 |